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Abstract
Compared to enteral or hypocaloric oral nutrition, the use of PN (par-
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Zusammenfassung
Im Vergleich zu einer enteralen bzw. hypokalorisch oralen Ernährung
ist die PE (parenterale Ernährung) nicht mit einer erhöhten Letalität,
Komplikationshäufigkeit insgesamt und Krankenhausverweildauer
verbunden. Das Risiko durch PE verursachter Komplikationen (wie z.B.
Refeeding-Syndrom,Hyperglykämie,Knochendemineralisierung,Kathe-
terinfektionen)kanndurcheinesorgfältigeÜberwachungdesPatienten
unddurchdenEinsatzvonErnährungsteams,besonderswährendeiner
Langzeit-PE, minimiert werden. Auftretende Komplikationen sind z.B.
das Refeeding-Syndrom bei Patienten mit ausgeprägter Mangelernäh-
rung, bei denen eine erneute Ernährung begonnen wird. Weitere
schwere Nebenwirkungen können metabolische und hepatische Kom-
plikationensein,wieeineHypertriglyzeridämie,Hyperglykämie,Fettleber,
Steatohepatitis, Cholestase, Cholezystitis, Cholelithiasis sowie Osteo-
malazie und Osteoporose. Die Effizienzkontrolle bei jeder Art von PE
kann zur Reduktion von PE-assoziierten Komplikationen und zur Kos-
tensenkungführen.UnterPEsollteWasser,-Elektrolyt-undZuckerhaus-
haltsowiediekardiozirkuläreFunktionengmaschigüberwachtwerden.
Regelmäßige Kontrollen der Serumelektrolyte und der Triglyzeride sind
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PatientenmitNierenfunktionsstörungen,beielektrolytfreierSubstratzu-
fuhr,Fettinfusionbzw.beiIntensivpatienten.DasmetabolischeMonito-
ring von Patienten unter längerfristiger PE sollte nach standardisierten
Schemataerfolgen.UnterLangzeit-PEsindzusätzlichdiemetabolischen
Determinanten des Knochenstoffwechsels überwachungspflichtig. Va-
riablen des Intermediär-, Elektrolyt- und Spurenelementstoffwechsels
bedürfen einer Kontrolle in regelmäßigen Abständen.
Schlüsselwörter: Refeeding-Syndrom, Hyperglykämie,
Hypertriglyzeridämie, Hepatopathie, Katheterinfektion
Complications
Preliminary remarks and general
information
Parenteral Nutrition (PN) is beneficial and life-saving in
a variety of clinical conditions, but can also result in nu-
merous, potentially serious, side-effects [1], [2]. The risk
of such complications can be minimised by carefully
monitoring patients and the use of nutrition support
teams.
One of the most dramatic side effects of PN is the so-
called refeeding syndrome, which can occur in severely
malnourished patients who are receiving aggressive PN.
In addition, hyperglycaemia can occur due to parenteral
carbohydrate intake in diabetic patients, in response to
postaggressionmetabolismorthesystemicinflammatory
response syndrome (SIRS), or due to systemic steroid
therapy. In extreme cases PN can result in a hyperosmol-
ar, hyperglycaemic non-ketotic coma.
Whensuddenlydiscontinuingparenteralintake,rebound
hypoglycaemia, although rare, may occur. Abnormalities
in the acid-base-balance can occur due to PN and may
resultinsignificantelectrolyteshifts.Hypertriglyceridemia
with dyslipoproteinaemia may occur. High carbohydrate
intakesmayresultinexcessivecarbondioxideproduction.
HepaticcomplicationsofPNincludesteatosis(fattyliver)
and cholestasis. Special complications like metabolic
bonediseasewihbonedemineralisationandosteoporosis
mayoccurinpatientsreceivinglong-termPN.Inallforms
of PN there is an imminent risk of infectious complica-
tions. Finally, intestinal side-effects (mucosal atrophy,
increased translocation of micro organisms and their
toxins) may also occur.
Relevanceofcomplicationsinshort-term
PN with respect to patient outcome
• Comparedtoenteralorhypocaloricoralnutrition,total
PN is not associated with increased mortality, overall
frequencyofcomplications,orlongerlengthofhospital
stay (LOS) (I).
Commentary
Benefits and side effects of PN have been the subject of
extensive literature analyses and intensive scientific dis-
cussions. The most extensive meta analysis on this topic
was presented by Koretz and co-workers in 2001 [3].
Eighty-tworandomisedcontrolledstudieswereevaluated
in which parenterally nourished patients received intra-
venous fluids with a mixture of amino acids and at least
10 kcal/kg body weight per day of non-protein calories.
Control patients were either not given intravenous nutri-
tionatall(onlyspontaneousoralfoodintake)orreceived
up to 5% glucose solutions intravenously as basal fluid
intake. PN did not significantly change either mortality or
morbidity (overall rate of complications)compared to the
control group. There was, however, a significant increase
in infectious complications (+5%) with PN, which caused
one additional infection per 20 PN treated patients. A
subgroupanalysisrevealedthatthisside-effectoccurred
mainly in tumour patients receiving oncologic therapy. In
other subgroups, for example perioperative patients, the
infection frequency was not increased. The overall LOS
with PN was not increased despite the increased inci-
dence of infection.
Afurthermeta-analysisonthefrequencyofcomplications
was published by Braunschweig and co-workers [4]. The
inclusion criteria varied from those of Koretz's analysis
in that only those studies were considered where the
calorie intake with PN either met or exceeded energy re-
quirements. Some 27 studies, with a total of 1829 pa-
tients, were identified comparing PN with appropriate
enteral intake. This analysis showed that infectious
complication incidence increased significantly when pa-
tientsreceivedPNrelativetopatientsinthecontrolgroup
who received either isocaloric enteral nutrition or oral
nutrition. Mortality was unaffected by PN. Malnourished
patientsreceivingPNhadalowerinfectionfrequencyand
a significantly lower mortality than those receiving only
oral food intake. The increased infectious morbidity is
likelyduetotherelativelyhighamountsofcarbohydrates
administered parenterally in some of the older studies
included in the analysis. The hyperglycaemic episodes
that must be expected with high dosage of parenteral
supplyareawell-knowncomplicationofPN.Theincidence
ofhyperglycaemiaisevidentlyhigherevenwithnormocal-
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[4].
Persistent hyperglycaemia and associated immunosup-
pressionare consideredcausalfactors for a poor patient
outcome [5], which would explain the better results of
themeta-analysisbyKoretzandco-workerswhoincluded
intheirmeta-analysisstudieswithaminimumdailyenergy
intake of approx. 15 kcal/kg body weight. The frequency
of infectious complications is probably reduced with a
low substrate intake and hence a low incidence of hyper-
glycaemia.
The known complications of PN caused a fierce contro-
versyin2003onclinicalbenefitsordamage[6].Apolem-
icpointofviewexpressed(“Deathbyparenteralnutrition”,
TPN = total poisonous nutrition) resulted in a numerous
responses[7],[8],[9]criticisingtheextremelyunbalanced
evaluationandpresentationoftheliterature,particularly
datafromanimalstudies.Theknownlinksbetweenintra-
venous energy supply, frequency of hyperglycaemia and
associated immune suppressive effects led experts to
conclude that PN would likely be without adverse effects
for patients if prescribed only when clinically indicated,
handled correctly and administered in appropriate
dosages [10], [11], [12]. Clear clinical benefits to justify
PN are given clinical indications, particularly in malnour-
ished patients with impaired gastrointestinal function.
Complication rates with short-term and
long-term PN
• Some complications (demineralisation of the bones,
catheter infections) occur more frequently with long-
termPNthanwithshort-termPNbecauseofmetabolic
alterations and venous access problems associated
with long-term PN (III).
Commentary
Inameta-analysisof37studiesevaluatinglong-termPN,
the most frequent complication was catheter sepsis with
0.34 episodes per catheter and year [13]. The second
most common complication was occlusion of the central
venous catheter, with 0.071 episodes per catheter and
year,andthethird,centralvenousthrombosiswith0.027
episodes per catheter and year. Pathological hepatic
changes with increased liver enzymes were found at
0.025 episodes per treatment year.
Metabolic bone changes are of significant clinical rele-
vance,astheymayresultinsevereillness.Slightchanges
in the bone metabolism probably occur frequently with
PN. In some studies, bone pain and fractures occur in
29% or more of long-term PN patients [1]. A multitude of
risk factors are associated with occurrence of these
complications,suchaslongtermsystemicsteroidtherapy,
short bowel syndrome, physical inactivity, menopause
and a genetic disposition for specific bone disorders.
Refeeding syndrome
• Initiationofrefeedinginpatientssufferingfromsevere
malnutrition may result in severe adverse effects, the
so-called refeeding syndrome (III).
Commentary
Refeeding syndrome is especially prevalent in severely
malnourishedpatientsandusuallyoccursduringthefirst
few days after initiating refeeding [14]. The exact inci-
dence is not known give a considerable heterogeneity of
studies. Although some of the symptoms are typical of
oral/enteral food intake (diarrhoea, nausea, vomiting),
most symptoms are observed both with enteral and par-
enteral refeeding. Among the several complications are:
• Vitamin B1 deficiency and acute beriberi,
• Volume overload with oedema, cardiac insufficiency
and lung oedema,
• Electrolyte disorders including hypophosphataemia,
hypokalemia and hypomagnesaemia,
• Arrhythmia (bradycardia, ventricular tachyarrhythmia)
• Glucose intolerance (hyperglycaemia, glucosuria, de-
hydration and hyperosmolar coma)
Intestinal complications
Altered intestinal function with total PN
• In contrast to data from animal studies, clinically rele-
vant changes in mucosal or intestinal function are
usually not induced in patients by receiving long-term
PN who are not critically ill. The extent to which this
also applies to critically ill patients is not known (II).
Commentary
An overview of studies examining the influence of total
PN on mucosal morphology or proliferation in patients
without severe malnutrition or critically illness is shown
in Table 1. All the studies available on this topic [15],
[16], [17], [18], [19], [20] used glutamine-free amino
acidsolutions.Despitethispotentialselectiveaminoacid
deficit, total parenteral energy intake reduced the height
of the villi only slightly or not at all, irrespective of the
underlyingillness.Thiswasalsothecaseinpatientswith
mild malnutrition. The enterocyte proliferation was not
affectedbyprolongedPN.Itisremarkablethatglutamine-
free total parenteral nutrition over a 2-months period
doesnotresultindistinctivechangesinmucosalmorpho-
logy [17].
Parallel to these discrete histological or histochemical
changes,proteinhomeostasiswasunalteredinthesmall
intestinal mucosa. Mucosal protein, DNA and RNA con-
tents remain unchanged with glutamine-free total PN for
over2 weeks[15], andtheconcentrationoffreeintercel-
lular amino acids also remains unaltered [21]. However,
selective functional changes are observed under
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glutamine-free PN despite complete maintenance of the
mucosalstructure.Enzymeactivitiesonthebrushborder
ofthemicrovilliarereduced[16].Furthermore,intestinal
permeability assessed by the lactulose/mannitol ratio
was increased after only 2 weeks of PN [15], [19]. The
clinical relevance of this increased permeability is not
clear,andtranslocationof(muchlarger)microorganisms
from the intestinal lumen was not demonstrated under
clinical conditions. Sedmann and co-workers [18] found
no effect of preoperative total PN on bacterial growth in
intestinal lymph nodes or on the intestinal serosa. These
studies were carried out on surgical patients who had
tissue samples surgically removed for microbiological
examination after total PN. Preoperative total PN, over
12 days, resulted in microbial growth in 3 out of 28 pa-
tients, whereas in enterally nourished patients, 14 out of
175 demonstrated the presence of microorganisms in
the lymph nodes of the serosa (not significant). It can be
concludedthat glutamine-freetotal PN does not result in
a significant loss of structural integrity of the intestinal
mucosa in patients who are not severely malnourished,
which differs from findings in rodents. A discrete loss of
function with reduced enzyme activity may be due to
preferential utilisation of amino acids for the synthesis
ofstructuralprotein,whichmightexplainwhythemucosal
anatomy is largely maintained.
There is lack of data for critically ill patients and severely
malnourishedpatients.Glutamine-freePNinducedmore
distinctive impairment in mucosal function of intensive
care patients. Duodenal protein content dropped signifi-
cantly in critically ill patients receiving PN already within
4 days [22]. There is also a limited nutrient absorption
and increased intestinal permeability in intensive care
patients [23]. The extent to which these processes are
influenced by PN, or only reflect an expression of an
overall poor general condition, has not been clarified.
Manyfindingsinanimalexperimentssofarhavenotbeen
validated in patients [12].
Hepatic and metabolic complications
• Metabolic and hepatic complications comprise hyper-
triglyceridemia, hyperglycaemia, fatty liver, non-alco-
holic fatty liver disease, cholestasis, cholecystitis,
cholelithiasis, osteomalacia and osteoporosis (III).
Commentary
Hypertriglyceridemia, hyperglycaemia, fatty liver, non-al-
coholic fatty liver disease, cholestasis, cholecystitis,
cholelithiasis,osteomalaciaandosteoporosisoccurafter
differentdurationsofPN[2],[12],[24].Whilehypertrigly-
ceridemiaandhyperglycaemiacanalsooccurwithshort-
term PN (intensive care), hepatic complications as well
as changes in the bones usually manifest themselves
after longer term PN for weeks, months or even years.
Hypertriglyceridemia
• Hypertriglyceridemiaisfoundinapproximately25–50%
of PN patients. The extent of hypertriglyceridemia de-
pends on the presence of accompanying hyper-
glycaemia, simultaneous renal insufficiency, steroid
administration, extent of the illness and the amount
of lipids infused (I).
• Severe hypertriglyceridemia (>1000 mg/dL or 11.4
mmol/L and particularly >5000 mg/dL or 57.0
mmol/L) can induce acute pancreatitis, similar to pa-
tients with severe hypertriglyceridemia without PN,
and it can affect micro circulation (I). It is not known
whetherlong-termhypertriglyceridemiainPNpatients
is associated with increased cardiovascular risk.
• Oneshouldaimforplasmatriglycerideconcentrations
below 400 mg/dL (4.6 mmol/L) during PN infusion
(C).
Commentary
A multicentre study demonstrated that not only the
dosage of intravenous lipids, but also a variety of other
factors (hyperglycaemia, renal insufficiency, steroid ad-
ministration, disease severity, simultaneous administra-
tion of heparin) influence the extent of hypertrigly-
ceridemia [25]. Severe PN-associated hypertrigly-
ceridemia may present a similar risk of pancreatitis as
severe hypertriglyceridemia of other origins. It is unclear
whether PN-associated hypertriglyceridemia, even when
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notasscoaitedwithanincreaseinlipoproteinscontaining
apolipoprotein B.
To manage hypertriglyceridemia the above-mentioned
causative factors should be corrected. Hyperglycaemia
plays an especially important role. Heparin activates
lipoprotein lipase and hence can lower blood triglyceride
levelsbutitincreasesnon-esterifiedfattyacidconcentra-
tions.
Hyperglycaemia
• Hyperglycaemia is found in up to 50% of PN patients.
Importantpredictorsareinsulinresistanceordiabetes
mellitus,severityoftheunderlyingillness,concomitant
steroid therapy, and the amount of glucose provided
(III).
• Hyperglycaemia adversely affects morbidity and mor-
tality in surgical and medical intensive care patients
(I).
• Normoglycaemia (approximately 80–145 mg/dL)
should be aimed for in critically ill patients to improve
outcome (A).
Commentary
Numerous clinical studies have associated hyper-
glycaemia with increased morbidity and mortality in sur-
gical patients with sepsis, patients after bypass surgery,
and patients with myocardial infarction or stroke [26],
[27], [28], [29], [30], [31], [32], [33], [34]. Experimental
data demonstrate a causal link between hyperglycaemia
and complications.
Itappearsimportanttotightlycontrolcontrolbloodsugar
in intensive care patients irrespective of simultaneous
PN administration. Hyperglycaemia is detected in up to
50% of intensive care patients who are not receiving PN,
and the rate increases with added PN [35]. A study in
surgical intensive care patients showed benefits of tight
blood glucose control (glucose 80–110 mg/dL) with re-
gards to mortality and morbidity when compared to con-
ventional blood sugar control (glucose 80–200 mg/dL)
[32]. A more recent study indicated a possible maximum
threshold of 145 mg/dL beyond which there are no add-
itional benefits [26]. Although a strict blood glucose con-
trol is linked to a more frequent rate of moderate
hypoglycaemia, this does not seem to pose a significant
clinicalproblemorhaveanyinfluenceonpatientoutcome
[26], [32] as long as strict blood glucose monitoring is
followed.
Acceptable blood glucose values for non-acutely ill pa-
tients receiving PN can not be determined based on
controlled studies. Possible complications are similar to
those seen in patients with diabetes mellitus. The risk of
infectious complications is increased due of venous ac-
cess for PN. The likelihood of hyperglycaemia induced
complications may depend on concomitant diseases,
duration of PN, and life expectancy. However, even in
case of limited life expectancy, lasting blood glucose
values over 200 mg/dL appear unacceptable because
they interfere with quality of life by inducing e.g. dehydra-
tion and polyuria.
Hepatic complications
• Hepatic complications of long-term PN are fatty liver,
non-alcoholic fatty liver disease and intrahepatic
cholestasis as well as cholecystitis and cholelithiasis.
Hepatic complications may occur in 15–40% of pa-
tients (III).
• Ursodeoxycholic acid may be tried in cholestatic liver
disease (B). Phenobarbital or antibiotics have no
demonstrated effect on hepatic complications (II).
• Biliary complications occur frequently – after 6 weeks
of therapy, up to 100% of patients have sludge in the
gallbladder (III).
• Establishing at least a minimal enteral food intake is
recommended to lower the risks of biliary complica-
tions (C).
Commentary
Fatty liver, non-alcoholic fatty liver disease, intrahepatic
cholestasis, cholecystitis and cholelithiasis may occur
with PN [36], [37]. Fatty liver is the most common com-
plication, whereas intrahepatic cholestasis or hepatitis
are less frequent. Hepatic complications are particularly
frequent in paediatric patients (cf. chapter “Neonato-
logy/Paediatrics” http://www.egms.de/en/gms/2009-
7/000074.shtml). The etiology of the hepatic complica-
tions is unclear. Various factors such as unbalanced nu-
tritional supply (excess or deficiency of specific amino
acids), hormonal factors, excess calories, lipids and bac-
terial overgrowth of the small intestine are discussed
[36], [37], [38], [39], [40]. Immaturity of the biliary
secretory system and early infections seem to play an
important role in paediatric patients. Potentially hepato-
toxic substances (drugs) should be avoided whenever
possible.
Most studies on the hepatic complications of PN either
refer to paediatric patients or were carried out at a time
whenamuchlargeramountofenergywasadministered.
Ursodeoxycholic acid, phenobarbital and gentamycine
havebeenevaluatedfortreatmenttherapyofPNinduced
cholestasisinclinicalstudies.Improvementofcholestasis
was reported with ursodeoxycholic acid but not with
phenobarbital or gentamycin [41], [42], [43].
Biliary complications are enhanced by a lack of enteral
food intake, while a minimal enteral nutrient intake may
largely prevent the occurrence of sludge [44]. Cholecys-
tokininandtherapidinfusionofaminoacidsolutionhave
been tested experimentally [36], [45], [46], [47] but not
as part of clinical routine where they seem impractical to
apply.
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Metabolic bone diseases
• Anadequateintakeofcalcium,phosphateandvitamin
DintakeshouldbeapproachedwithPNtohelpprevent
and treat osteoporosis and osteomalacia (C).
• Bisphosphonates may be used for treating low bone
density associated with PN (C).
Commentary
The prevalence and pathogenesis of osteomalacia and
osteoporosis associated with PN is unclear, with the re-
ported prevalence ranging from rare cases to up to 40%
ofpatientswithlong-termPN.Bonechangesareprobably
linked to supoptimal calcium, phosphate and vitamin D
intakes, lack of physical activity, lack of light exposure
with poor vitamin D status, and side-effects of other
therapies (e.g. heparin, steroids) [48]. Therapeutic
measures involve approaching adequate substrate in-
takes as well as preventing other risks. A small study
show improved bone density in PN patients receiving
pamidronate [49].
Monitoring
Monitoring of clinical efficiency
• Regular monitoring is necessary in all types of PN. Ef-
ficientmonitoringcanresultinreducedPN-associated
complications and reduced costs (A).
Commentary
PN is associated with significant costs and sometimes
serious complications. Regular clinical monitoring and
diligent care of the patient are necessary to support a
goodoutcome.Nutritionalmonitoringofpatientsreceiving
PN is needed to determine efficiency, to discover and
prevent complications, and to document changes in the
clinical course. Monitoring should preferably be carried
outbyanutritionsupportteam,whichmonitorsefficiency
and sufficiency of PN with regards to specific endpoints.
The definition of these endpoints should depend on the
underlying illness of the patient, his/her clinical state,
the facilities available in the institution caring for the pa-
tient, and the requests of the individual patient [5], [14],
[50], [51].
The aims of PN should be established according to spe-
cific markers and targets when the decision for PN is
made.Thesegoalscanincludethemaintenanceorregen-
eration of protein inventory in cells, a drop in morbidity
and mortality, an improvement in quality of life or an im-
provement in clinical variables, e.g. a drop in LOS or
treatment costs.
Most studies carried out on patients receiving artificial
nutrition use surrogate variables of nutritional state as
targets for outcome (Table 2). These markers include
energybalance,measuresofbodycompositionandbody
weight,determinationofspecificserumproteins,nitrogen
balance, and functional outcomes [20]. Many of these
parameters are influenced by the course of disease or
injury and thus, do not only reflect nutritional supply.
Nutritionalstateisanintermediatemarker;whiletheaim
of PN should ultimately be improvement in the clinical
course and outcome. The monitoring of such clinical
variables like quality of life, morbidity and mortality, as
well as LOS and costs is clearly more relevant.
NumerousclinicalstudiesmonitoredPNpatients,accord-
ing to defined protocols, to evaluate the efficiency of a
nutritional regime with certain markers. Such studies
have been carried out in intensive care patients with
polytrauma,andinperioperativepatients.Mostfrequently
nitrogen balance, concentrations of specific serum pro-
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of the efficiency of a certain nutrition regime [52].
The extent to which such monitoring improves the pa-
tient’sclinicaloutcomessuchasmorbidity,mortality,and
quality of life is unknown, but it is concluded that such
monitoring is associated with an improved cost-benefit
ratio. Three randomised prospective studies analysed
the efficiency of nutritional monitoring on prognosis and
costs[20],[25],[53].Themainoutcomewasasignificant
drop in complications and costs compared to studies in
which such monitoring was not applied.
Itisalsoimportanttoperformtarget-oriented,consecutive
re-evaluations of nutritional state. The parenteral sub-
stratesupplyshouldbecomparedtothepredictedenergy
and protein requirements. Changes in the clinical state
and level of activity may require a periodic recalculation
ofenergyrequirements.Indirectcalorimetrycanbeused,
if the course appears to be unsatisfactory, to determine
changes in the energy requirements and expenditure
[54].
The requirement for total PN therapy should be regularly
reevaluated, particularly to explore whether it might be
complemented or replaced by enteral or oral feeding.
Metabolic complications
Measures to prevent the refeeding syndrome
• Water and electrolyte balance, blood sugar, and car-
diovascular function should be regularly monitored in
patients receiving PN in order to detect a refeeding
syndrome (C).
Commentary
Severely malnourished patients, in whom PN is provided
after a long period of fasting, need to be strictly moni-
tored.Waterbalance,cardiovascularfunctionandserum
electrolytes should be carefully monitored at the start
andduringPN.Serumelectrolyteshifts,particularlyhypo-
kalemia and hypophosphataemia, should be corrected
before starting PN. Sufficient thiamine intake should be
established prior to PN. During the first week of PN, fluid
intake should be limited to approximately 800 ml/day
pluscompensationforinsensiblelossestherebyavoiding
both fluid overload and dehydration. Daily monitoring of
body weight can aid in determining the necessary fluid
volume. A weight gain of >0.25 kg/day or 1.5 kg/week
likely is typically indicative of fluid accumulation and not
of an improved nutritional state. The amount of carbo-
hydrates administered daily should not exceed 2–3 g/kg
bodyweight/dayandbloodglucoseconcentrationshould
be strictly monitored because of the high risk of hyper-
glycaemia.Patientswithnormalrenalfunctionshouldbe
generously substituted with phosphate, potassium and
magnesium with appropriate laboratory checks. It is ne-
cessarytocheckalsothefluidbalance(fluidintake,urine
production) on a daily basis [14].
Blood glucose monitoring
• Depending on the patient's individual risk, blood glu-
cose should be closely checked during PN in view of
an inverse correlation between the extent or duration
of hyperglycaemia and patient outcome (A).
Commentary
Hypo-andhyperglycaemiaarethemostseveremetabolic
complications occuring in patients receiving PN. Some
7% of patients on PN who receive a maximum of 5
mg/kg/min. glucose, develop hyperglycaemia (blood
glucose >200 mg/dL). If patients receive more than 5
mg/kg/min glucose, the hyperglycaemia rate rises to al-
most 50% [51]. Patients with diabetes mellitus, systemic
steroidtherapyororganfailurewereexcludedinthelatter
study. In extreme cases, such hyperglycaemia can result
inhyperosmolarhyperglycaemiccoma,andmortalitycan
increase up to 14% in patients over 50 years of age [50].
In addition to increased blood glucose concentrations,
neurological symptoms like dementia, slowdown or leth-
argyoftenoccur,precedingtheactualcoma.Thus,careful
andregularexaminationofclinical-neurologicalsymptoms
is necessary for monitoring and diagnosis of hyper-
glycaemia-associated side effects. It is recommended
thatthemaximumglucoseintakeshouldnotexceed3–4
mg/kg/min.
Hyperglycaemic complications are intensified by under-
lyingdiseasesuchasdiabetesmellitusorsurgicaltrauma.
Strictcontrolandmonitoringofbloodglucoseconcentra-
tion (diurnal blood glucose profile with 3–4 values daily)
is recommended particularly in these patients, because
hyperglycaemia is associated with impaired immune
function and increased rates of infection.
The frequency of severe hypoglycaemia whilst receiving
insulintherapy(asanadjuncttoPN)hasgreatlyincreased
because of the wide use of intravenous insulin for
lowering of blood glucose concentration below 150
mg/dL. The incidence ranges between 4 and 5% [5] and
is accompanied by severe neurological function deficits.
Therefore, it is of utmost importance to strictly control
thebloodglucoseconcentrationespeciallywithintraven-
ousinsulintherapy.Checksmaybecarriedoutevery2–3
hours in unstable patients and those with short-term in-
sulin dosage changes [20].
Special attention is necessary if there is a sudden with-
drawal of carbohydrate and insulin intake under insulin
therapy. Severe hypoglycaemia can occur due to the
longer biological effect of insulin (15–30 min). It may be
necessary to prophylactically continue the carbohydrate
supply beyond the end of insulin supply in case of low
blood glucose levels to prevent rebound hypoglycaemia
with unmeasurably low blood glucose concentrations.
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Further monitoring measures
• Regularchecksofserumelectrolytesandtriglycerides
are necessary with PN (A).
• Enhanced monitoring is necessary in patients with
alteredrenalfunction,electrolyte-freesubstrateintake,
lipid infusions, and in intensive care patients (C).
• The metabolic monitoring of patients under long-term
PN should be carried out according to standardised
procedures (C).
Commentary
Marked increases in plasma triglyceride concentrations
may occur in patients receiving intravenous lipids. The
frequencyofsuchhypertriglyceridemiaduringa7-dayPN
is up to 26% in unselected patients[25]. If left unnoticed
anduntreated,severehypertriglyceridemiamightinduce
pancreatitis and changes in lung function. Therefore,
regular monitoring of plasma triglyceride concentrations
whilst providing parenteral lipid intake is recommended.
Pathologicalalterationsoftheacid-basestatusareoften
observedinPNpatients.Onaverage,pathologicalpartial
pressuresofCO2arepresentin13%ofcases,andabnor-
mal values for serum chloride concentrations are found
in 1–7% of cases [52]. These changes occur as a result
of PN induced increases in glucose oxidation or associ-
ated CO2 production.It may be difficult to correctspecific
imbalancesthatdevelopwithsevereileusorrenalfailure
when using fixed, predetermined electrolyte concentra-
tions in the PN solutions. As acid-base balance and
electrolyte balance are closely linked, serum electrolytes
as well as the acid-base status should be regularly
monitored, particularly in intensive care patients and
patientswithalteredrenalfunction.Thenecessarytargets
for the monitoring of complications are shown in Table 3
and Table 4.
Special monitoring measures in
long-term PN patients
• The metabolic determinants of bone metabolism
should be monitored in patients receiving long-term
PN. Markers of intermediary, electrolyte and trace
element metabolism require regular checks (C).
Commentary
Maintenance of physiological bone metabolism requires
adequate serum concentrations of vitamin D, calcium,
magnesium and phosphate. In long-term PN patients,
severe disorders resulting in osteoporosis and fractures
may occur. The parenterally administered substrates or
cyclic infusion favour renal calcium excretion. This hyper-
calciuria is closely associated with the PN associated
metabolic bone disease (PN-MBD) [54].
Monitoring of bone density by dual energy X-ray absorp-
tiometry (DEXA) or peripheral quantitative computer
tomography(pqCT)isrecommended.Recommendations
areavailablefordiagnosingormonitoringat-riskpatients
or patients with bone-related complaints (Table 5) [54].
Notes
This article is part of the publication of the Guidelines on
Parenteral Nutrition from the German Society for Nutri-
tional Medicine (overview and corresponding address
under http://www.egms.de/en/gms/2009-7/000086.
shtml).
English version edited by Sabine Verwied-Jorky, Rashmi
Mittal and Berthold Koletzko, Univ. of Munich Medical
Centre, Munich, Germany.
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